Harvard Management Company’s Pliant Therapeutics PLRX Stock Holding History

Harvard Management Company’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-281,189	Closed	-$7.48M	–	44
2023 Q1	$7.48M	Sell	281,189 -281,190	-50%	-$8.01M	0.79%	19
2022 Q4	$10.9M	Hold	562,379	–	–	1.35%	10
2022 Q3	$11.7M	Hold	562,379	–	–	1.46%	11
2022 Q2	$4.5M	Hold	562,379	–	–	0.52%	24
2022 Q1	$3.94M	Hold	562,379	–	–	0.4%	31
2021 Q4	$7.59M	Hold	562,379	–	–	0.71%	29
2021 Q3	$9.49M	Hold	562,379	–	–	0.56%	24
2021 Q2	$16.4M	Hold	562,379	–	–	0.94%	18
2021 Q1	$22.1M	Hold	562,379	–	–	1.24%	15
2020 Q4	$12.8M	Hold	562,379	–	–	0.69%	16
2020 Q3	$12.7M	Hold	562,379	–	–	0.7%	14
2020 Q2	$18.3M	Buy	+562,379	New	+$14.9M	1.56%	9

Other funds holding PLRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Harvard Management Company's PLRX Position: Q2 2023 in Review

Harvard Management Company sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 281,189 shares — an estimated $7.48M sold.

Harvard Management Company first reported a position in PLRX in Q2 2020 and held it in 12 quarters. The position peaked at $22.1M in Q1 2021. 143 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

Harvard Management Company reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
Harvard Management Company sold 281,189 Pliant Therapeutics shares in Q2 2023, an estimated $7.48M.
Harvard Management Company first reported a position in Pliant Therapeutics in Q2 2020 and held it in 12 quarters.
Harvard Management Company's Pliant Therapeutics position peaked at $22.1M in Q1 2021.
143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.